Abstract:
A method and reagent for the simultaneous or independent enumeration of reticulocytes in a whole blood sample, without the need to separately incubate the sample and reagent. The reagent contains a reticulocyte staining amount of an unsymmetrical cyanine dye, from about 40 mM to about 60 mM of a buffer selected from the group consisting of imidazole, Tris and Bis-Tris and a dye stabilizing amount of a non-ionic surfactant selected from the group consisting of N, N-bis[3-D-Glucon-amidopropyl] cholamide and a polyoxypropylene-polyoxyethylene block copolymer. The reagent has a pH from about 6.8 to about 7.2 and an osmolarity adjusted to about 280 to about 310 mOsm/l with a mono- or divalent alkali salt selected from the group consisting of NaCl, KCl, LiCl, CaCl2, MgCl2 and ZnCl2. The method utilizes the reagent in a no incubation process that also allows for the simultaneous determination of CBC as well as reticulocyte counts and maturity indices.
Abstract:
The present invention provides compounds of formula (I) and the pharmaceutically acceptable salts thereof which are potent antagonists of PAF and are useful in the treatment of PAF-related disorders including asthma, shock, respiratory distress syndrome, acute inflammation, transplanted organ rejection, gastrointestinal ulceration, allergic skin diseases, delayed cellular immunity, parturition, fetal lung maturation, and cellular differentiation.
Abstract:
Immunoassay reagents, methods and test kits for the specific quantification of vancomycin in a test sample are disclosed. The reagent comprises antibodies prepared with immunogens of Figure 6 wherein P is an immunogenic carrier material and X is a linking moiety. Also described is the synthesis of labeled reagents of Figure 8 wherein Q is a detectable moiety, preferably fluorescein or a fluorescein derivative, and X is a linking moiety.
Abstract:
A controlled-release formulation comprising, in combination a therapeutically-effective dosage of drug which melts at low temperature and an additive selected from the group consisting of ethyl cellulose, methylcellulose, hydroxypropyl cellulose, polyacrylamide, ethylene vinyl acetate copolymer, polymethylmethacrylate, polyhydroxyethyl methacrylate and waxes, and the like, such that the additive and the drug form a homogeneous drug-additive composite with a 92-to-97 % weight/weight of said drug, wherein said drug is selected from the group consisting of: sodium hydrogen divalproex, ibuprofen, ramipril, dibenzyline, erythrityl tetranitrate, isosorbide dinitrate, methosuximide, ketoprofen, gemfibrozil, paroxetine hydrochloride, and trimipramine maleate.
Abstract:
Embodiments described herein relate to a valve (10) and a method of use. In one embodiment, a first element (24) is operatively and removably positioned with respect to a first fluid conveying conduit (16) and a second fluid conveying conduit (18). The first element (24) is movable between a first position where no fluid communicates between the first fluid conveying conduit and the second fluid conveying conduit and a second position where fluid communicates between the first fluid conveying conduit and the second fluid conveying conduit. A second element (26) is operatively and removably engageable with the first element for maintaining operative position of the first element with respect to the first fluid conveying conduit and the second fluid conveying conduit. A third element (28) is operatively and removably engageable with the second element for maintaining engagement between the first element and the second element.
Abstract:
A heater (12) for a catheter (10) used in monitoring constant cardiac output is fabricated using a bifilar wire (21) coated with polyvinyl chloride (PVC) like that used for the catheter. The bifilar wire is coated with the PVC using a conventional extrusion technique, producing a coated lead (24, 32). The coated lead is wrapped around the exterior surface of the catheter, forming a helical coil. Heat is applied to the coated lead to melt the PVC coating, causing it to bond the lead to the catheter. The melted PVC also flows into gaps (23) or notches between adjacent coils of the lead, producing a relatively smooth outer surface for the heater when cooled.
Abstract:
The invention is related to a novel strain(s) of Bacillus thuringiensis in which essentially all of the pesticidal activity of said strain is in the supernatant of a fermentation of said strain. The strain produces a substance which has activity against an insect pest(s) of the order Coleoptera and which enhances the pesticidal activity of a Bacillus related pesticide. The invention further relates to pesticidal compositions comprising the substance and a pesticidal carrier, or the substance and a Bacillus related pesticide, a chemical pesticide and/or a virus with pesticidal properties as well as methods of using the pesticidal compositions to control a pest.
Abstract:
The present invention provides a plasmid containing a promoter sequence, a nucleotide sequence encoding an exogenous protein, and a nucleotide sequence encoding an enzyme capable of modifying the exogenous protein. In a specific embodiment of the invention the encoded exogenous protein is human beta -casein and the encoded enzyme is a human kinase capable of phosphorylating recombinant beta -casein in a bacterial system.
Abstract:
A testing apparatus is disclosed which is useful for determining if air filters are providing clean/sterile air within acceptable aseptic processing and/or clean room operation acceptable contaminant levels. The advantage of the disclosed testing apparatus is that air filters may be tested "on-line" during a production process as opposed to the traditional testing methods which included removal of air filter for off-line testing. Less down-time is experienced using the disclosed testing system. A series of valves positioned at the outputs from the air filters, which allow communication with a particle counter, are controlled by a computer which sequentially activates the valves to test the contamination level of the air which passed through an air filter during the production process.
Abstract:
A solution administration apparatus for patient care, for use with an associated solution administration system, which apparatus includes a laser drilled orifice flow control device to provide a controlled, predetermined flow rate of solution to the patient. The apparatus includes a tubing set and a laser drilled orifice flow restrictor, formed in a body, and in fluid communication therewith, for use with an associated fluid supply container. The system provides a controlled, predetermined flow rate of solution to the patient which is independent of, and relatively constant over minor variations in solution supply pressure and viscosity.